Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cytosorbents Corp - SIC # 3845 - ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS
Ticker
Exchange
SIC #
Website
Latest Ticker
CTSO
Nasdaq
3845
http://cytosorbents.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cytosorbents Corp
CytoSorbents Highlights New Clinical Data from Current Studies at the Live 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM)
- Mar 22nd, 2023 12:09 pm
Investors in Cytosorbents (NASDAQ:CTSO) have unfortunately lost 57% over the last five years
- Mar 20th, 2023 11:38 am
CTSO: UPDATE: CytoSorbents reports 4th quarter and fiscal 2022 financial and operating results which showed positive revenue growth on a Core Product constant currency basis.
- Mar 17th, 2023 1:10 pm
CytoSorbents Comments on Bank Exposure and Diversified Cash Position
- Mar 14th, 2023 11:00 am
Cytosorbents Corporation (NASDAQ:CTSO) Q4 2022 Earnings Call Transcript
- Mar 13th, 2023 6:53 am
Q4 2022 Cytosorbents Corp Earnings Call
- Mar 10th, 2023 3:33 pm
CytoSorbents Reports Fourth Quarter and Full Year 2022 Results
- Mar 9th, 2023 9:15 pm
New European “Guidelines for the Management of Severe Perioperative Bleeding” Consider Hemoadsorption for the First-Time
- Mar 7th, 2023 12:00 pm
CytoSorbents to Present at the Cowen 43rd Annual Health Care Conference
- Feb 27th, 2023 12:00 pm
CytoSorbents to Report Fiscal 2022 Operating and Financial Results
- Feb 24th, 2023 12:00 pm
Quite a few insiders invested in Cytosorbents Corporation (NASDAQ:CTSO) last year which is positive news for shareholders
- Feb 21st, 2023 11:22 am
CTSO: INITIATION: Established medical device company with advanced proprietary blood purification technologies positioned for rapid profitable growth going forward.
- Feb 15th, 2023 1:20 pm
CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2022 Revenue
- Jan 31st, 2023 12:15 pm
Cytosorbents Corporation's (NASDAQ:CTSO) market cap touched US$103m last week, benefiting both individual investors who own 52% as well as institutions
- Jan 29th, 2023 2:58 pm
CytoSorbents Announces Health Canada Regulatory Approval For Pivotal STAR-T Trial
- Jan 23rd, 2023 12:00 pm
CytoSorbents Appoints Irina B. Kulinets, PhD, as Senior Vice President of Global Regulatory Affairs
- Jan 17th, 2023 12:00 pm
Can Cytosorbents (NASDAQ:CTSO) Afford To Invest In Growth?
- Jan 12th, 2023 12:16 pm
CytoSorbents Receives $5M in Non-Dilutive Debt Financing from Bridge Bank and Extends Loan Agreement
- Dec 29th, 2022 12:00 pm
CytoSorbents Receives Recommendation from Independent Data and Safety Monitoring Board to Continue Pivotal STAR-T Trial As Planned Without Modifications
- Dec 21st, 2022 12:00 pm
These Analysts Think Cytosorbents Corporation's (NASDAQ:CTSO) Sales Are Under Threat
- Nov 17th, 2022 10:21 am
Scroll